Zheng Quan Zhi Xing·2025-08-01 08:46Market Overview - The A-share market experienced a technical adjustment with all three major indices slightly declining, reflecting a market structure that necessitates a pullback after rapid gains [2][9] - The Shanghai Composite Index fell by 0.37%, the Shenzhen Component Index by 0.17%, and the ChiNext Index by 0.24%, with over 3,300 stocks rising throughout the market [1][2] Sector Performance - The pharmaceutical sector showed resilience, with companies like Angli Kang (002940) and Weikang Pharmaceutical (300878) hitting the daily limit [1] - The photovoltaic sector rebounded, supported by regulatory measures aimed at enhancing energy efficiency in the polysilicon industry, leading to price stabilization across the supply chain [3] - The logistics and express delivery sector strengthened due to recent regulatory discussions aimed at promoting high-quality development and addressing competitive issues [4] Investment Trends - The innovation drug sector continues to thrive, with a positive outlook for Chinese innovative drugs entering international markets, although short-term volatility may increase [5] - Financing balance in A-shares reached a ten-year high of 1.971 trillion yuan, indicating strong market risk appetite, with net purchases exceeding 130 billion yuan in July [6][7] - A significant portion of the financing activity was concentrated in the pharmaceutical, electronics, and non-ferrous metals sectors, with notable net purchases [7][8] Future Outlook - Analysts suggest that despite the current technical adjustments, the medium-term upward trend in A-shares remains intact, with average P/E ratios indicating a favorable environment for long-term investments [9] - Investment strategies should focus on high-growth technology sectors, industries with strong earnings support, and potential opportunities arising from policy changes [10]